• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement

    3/4/25 1:18:32 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIPO alert in real time by email

    New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in this private offering.

    The proceeds from this offering will further Lipella's mission to develop innovative therapies addressing significant unmet medical needs, while also funding general corporate purposes.

    Jonathan Kaufman, PhD, CEO of Lipella Pharmaceuticals, remains committed to leading the company's groundbreaking clinical pipeline and advancing transformative treatments.

    "We are honored to serve as the sole placement agent in this private placement for Lipella Pharmaceuticals," said John Lowry, CEO of Spartan Capital Securities. "Lipella's dedication to medical innovation and improving patient outcomes is commendable. This successful transaction underscores both the strength of Lipella's vision and Spartan Capital's commitment to facilitating impactful investment opportunities. We look forward to supporting Lipella's continued success."

    Sichenzia Ross Ference Carmel LLP served as placement agent counsel, while Sullivan & Worcester LLP acted as counsel to Lipella Pharmaceuticals Inc.

    Further details on the transaction will be available in the Company's Form 8-K, to be filed with the U.S. Securities and Exchange Commission and accessible at www.sec.gov.

    The common shares and the common shares issuable upon the conversion of related warrants have not been registered under the Securities Act of 1933, as amended, or any state securities laws. Until registered, these securities may not be offered or sold in the United States or any state absent registration or an applicable exemption from registration requirements.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under applicable securities laws.

    About Spartan Capital Securities, LLC

    Spartan Capital Securities, LLC is a premier full-service investment banking firm offering a comprehensive range of advisory services to institutional clients and high-net-worth individuals. Known for its expertise in capital raising, strategic advisory, and asset management, Spartan Capital delivers tailored solutions to meet clients' financial goals.

    For more information about Spartan Capital Securities, visit www.spartancapital.com.

    Contact: Spartan Capital Securities, LLC 45 Broadway, 19th Floor New York, NY 10006 [email protected]



    Primary Logo

    Get the next $LIPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIPO
    SEC Filings

    View All

    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

    2/4/26 4:19:37 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.

    10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

    11/14/25 4:46:29 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

    10/21/25 4:18:04 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

    All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week timepointPreparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration PITTSBURGH, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced positive final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in pa

    9/18/25 8:00:00 AM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus

    PITTSBURGH, Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced that Jonathan Kaufman, Chief Executive Officer of Lipella, will present a corporate overview and final results from Phase 2a trial of LP-10 in oral lichen planus at the Zacks SCR Life Sciences Virtual Investor Forum on September 18th, 2025 at 12:30pm EDT. Event Details: To register for the event and access the Lipella presentation webcast, click on th

    9/15/25 8:00:00 AM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

    PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange. In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitmen

    6/25/25 3:15:00 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

    4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

    5/15/24 4:39:19 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

    4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

    3/19/24 6:21:08 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Kaufman Jonathan H

    4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

    4/7/25 7:16:11 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Kaufman Jonathan H

    4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

    3/17/25 8:12:52 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Kaufman Jonathan H

    4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

    3/11/25 8:01:27 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:09:22 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:00:15 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

    SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    10/17/24 5:00:44 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care